Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

264.92
+1.410.53%
Pre-market: 262.00-2.9200-1.10%06:37 EDT
Volume:417.85K
Turnover:110.05M
Market Cap:17.54B
PE:20.44
High:265.50
Open:265.00
Low:260.00
Close:263.52
52wk High:282.15
52wk Low:186.05
Shares:66.19M
Float Shares:65.54M
Volume Ratio:0.74
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):12.96
EPS(LYR):-4.4176
ROE:118.78%
ROA:9.58%
PB:10.58
PE(LYR):-59.97

Loading ...

Analysts’ Top Healthcare Picks: Amylyx Pharmaceuticals Inc (AMLX), Ascendis Pharma (ASND)

TIPRANKS
·
Jun 16

Ascendis Pharma's Yorvipath Has Superior Profile Relative to Competitors, Wedbush Says

MT Newswires Live
·
Jun 15

Ascendis reports sustained efficacy, safety for TransCon PTH in PaTHway hypoparathyroidism trial at Week 182

Reuters
·
Jun 15

Ascendis Pharma completes Phase 3 PaTHway Trial

TIPRANKS
·
Jun 15

Ascendis says Phase 3 PaTHway trial shows TransCon PTH sustains hypoparathyroidism benefits through Week 182

Reuters
·
Jun 14

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

GlobeNewswire
·
Jun 14

MBX's Flagship Drug Trial Met Expectations But Perhaps Some Investors Wanted More -- Market Talk

Dow Jones
·
Jun 13

European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week

MT Newswires Live
·
Jun 12

Ascendis says Phase 2 trial shows TransCon PTH sustains hypoparathyroidism benefits at 5 years

Reuters
·
Jun 12

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

GlobeNewswire
·
Jun 12

Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer

TIPRANKS
·
Jun 09

Ascendis presents final Phase 3 PaTHway results for palopegteriparatide in adult hypoparathyroidism at ENDO 2026

Reuters
·
Jun 09

Ascendis Pharma to present rare endocrine disease data at Endocrine Society ENDO meeting

Reuters
·
Jun 09

Ascendis Pharma CFO Scott Thomas Smith acquires 100 common shares valued at $21,900

Reuters
·
Jun 03

Ascendis Pharma director Jean Jacques Bienaime acquires USD 111,986 in common shares

Reuters
·
Jun 02

Ascendis Pharma CFO Scott Thomas Smith acquires $55,830 of ordinary shares

Reuters
·
Jun 02

Ascendis Pharma director Jean Jacques Bienaime reports purchase of ordinary shares worth $95,120.5

Reuters
·
May 28

European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading

MT Newswires Live
·
May 26

J.P. Morgan Remains a Buy on Ascendis Pharma (ASND)

TIPRANKS
·
May 20

Ascendis Pharma Initiated at Buy by Citigroup

Dow Jones
·
May 19